Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Mar 18, 2010

Premium

Traversa Therapeutics has appointed Bharat Chowrira to its board of directors.

Chowrira is currently COO and senior vice president of biopharmaceutical firm Nektar Therapeutics. Before this, he was executive director of worldwide licensing and external research at Merck.

Chowrira joined Merck after its acquisition of RNAi drug shop Sirna Therapeutics, where he served as vice president.

He holds a PhD in microbiology and molecular genetics from the University of Vermont and a JD from the College of Law at the University of Denver.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.